We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » IRB’s Approval of Studies Comes Under FDA Fire
IRB’s Approval of Studies Comes Under FDA Fire
December 9, 2009
The Burzynski Research Institute’s IRB failed to discuss a member’s concerns about the source of an investigational drug for a safety and efficacy study and the need for a patient risk-benefit analysis, an FDA warning letter says.